Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of HCV infection by targeting microRNA.

The New England journal of medicine - 2 May 2013

Janssen Harry L A, Reesink Hendrik W, Lawitz Eric J, Zeuzem Stefan, Rodriguez-Torres Maribel, Patel Keyur, van der Meer Adriaan J, Patick Amy K, Chen Alice, Zhou Yi, Persson Robert, King Barney D, Kauppinen Sakari, Levin Arthur A, Hodges Michael R

Abstract excerpt

BACKGROUND: The stability and propagation of hepatitis C virus (HCV) is dependent on a functional interaction between the HCV genome and liver-expressed microRNA-122 (miR-122). Miravirsen is a locked nucleic acid-modified DNA phosphorothioate antisense oligonucleotide that sequesters mature miR-122 in a highly stable heteroduplex, thereby inhibiting its function. METHODS: In this phase 2a study at seven...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Injections, Subcutaneous

Share to MicroRNAs

Share to Oligonucleotides

Share to RNA, Viral

Source

Identifiers

PMID: 23534542
DOI: 10.1056/NEJMoa1209026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of HCV infection by targeting microRNA.PMID 23534542Read ↗

In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.Semantic proximity Read ↗

miR-122-based therapies select for three distinct resistance mechanisms based on alterations in RNA structure.Semantic proximity Read ↗

Unraveling the Mysterious Interactions Between Hepatitis C Virus RNA and Liver-Specific MicroRNA-122Semantic proximity Read ↗

MicroRNA-122 Regulation of HCV Infections: Insights from Studies of miR-122-Independent ReplicationSemantic proximity Read ↗

58 FINAL RESULTS – RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY, ANTI-VIRAL PROOF-OF-CONCEPT STUDY OF MIRAVIRSEN, AN OLIGONUCLEOTIDE TARGETING MIR-122, IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTIONSemantic proximity Read ↗

Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus InfectionSemantic proximity Read ↗

MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR.Semantic proximity Read ↗

MicroRNAs, Hepatitis C Virus, and HCV/HIV-1 Co-Infection: New Insights in Pathogenesis and TherapySemantic proximity Read ↗

LO7 : A single subcutaneous dose of 2mg/kg or 4mg/kg of RG-101, a GalNAc-conjugated oligonucleotide with antagonist activity against MIR-122, results in significant viral load reductions in chronic hepatitis C patientsSemantic proximity Read ↗

Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapySemantic proximity Read ↗

Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?Semantic proximity Read ↗

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B InfectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.